286 related articles for article (PubMed ID: 30833304)
1. ADAM17 selectively activates the IL-6 trans-signaling/ERK MAPK axis in KRAS-addicted lung cancer.
Saad MI; Alhayyani S; McLeod L; Yu L; Alanazi M; Deswaerte V; Tang K; Jarde T; Smith JA; Prodanovic Z; Tate MD; Balic JJ; Watkins DN; Cain JE; Bozinovski S; Algar E; Kohmoto T; Ebi H; Ferlin W; Garbers C; Ruwanpura S; Sagi I; Rose-John S; Jenkins BJ
EMBO Mol Med; 2019 Apr; 11(4):. PubMed ID: 30833304
[TBL] [Abstract][Full Text] [Related]
2. The ADAM17 protease promotes tobacco smoke carcinogen-induced lung tumorigenesis.
Saad MI; McLeod L; Yu L; Ebi H; Ruwanpura S; Sagi I; Rose-John S; Jenkins BJ
Carcinogenesis; 2020 Jun; 41(4):527-538. PubMed ID: 31257400
[TBL] [Abstract][Full Text] [Related]
3. The protein kinase MAP3K19 phosphorylates MAP2Ks and thereby activates ERK and JNK kinases and increases viability of KRAS-mutant lung cancer cells.
Hoang VT; Nyswaner K; Torres-Ayuso P; Brognard J
J Biol Chem; 2020 Jun; 295(25):8470-8479. PubMed ID: 32358059
[TBL] [Abstract][Full Text] [Related]
4. Oncogenic KRAS promotes growth of lung cancer cells expressing SLC3A2-NRG1 fusion via ADAM17-mediated shedding of NRG1.
Shin DH; Kim SH; Choi M; Bae YK; Han C; Choi BK; Kim SS; Han JY
Oncogene; 2022 Jan; 41(2):280-292. PubMed ID: 34743207
[TBL] [Abstract][Full Text] [Related]
5. Protein kinase Cα suppresses Kras-mediated lung tumor formation through activation of a p38 MAPK-TGFβ signaling axis.
Hill KS; Erdogan E; Khoor A; Walsh MP; Leitges M; Murray NR; Fields AP
Oncogene; 2014 Apr; 33(16):2134-44. PubMed ID: 23604119
[TBL] [Abstract][Full Text] [Related]
6. iRhom2 regulates ERBB signalling to promote KRAS-driven tumour growth of lung cancer cells.
Sieber B; Lu F; Stribbling SM; Grieve AG; Ryan AJ; Freeman M
J Cell Sci; 2022 Sep; 135(17):. PubMed ID: 35971826
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic Kras promotes chemotherapy-induced growth factor shedding via ADAM17.
Van Schaeybroeck S; Kyula JN; Fenton A; Fenning CS; Sasazuki T; Shirasawa S; Longley DB; Johnston PG
Cancer Res; 2011 Feb; 71(3):1071-80. PubMed ID: 21148749
[TBL] [Abstract][Full Text] [Related]
8. Circulating Soluble IL-6R but Not ADAM17 Activation Drives Mononuclear Cell Migration in Tissue Inflammation.
Schumacher N; Schmidt S; Schwarz J; Dohr D; Lokau J; Scheller J; Garbers C; Chalaris A; Rose-John S; Rabe B
J Immunol; 2016 Nov; 197(9):3705-3715. PubMed ID: 27698010
[TBL] [Abstract][Full Text] [Related]
9. An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer.
Wang H; Lv Q; Xu Y; Cai Z; Zheng J; Cheng X; Dai Y; Jänne PA; Ambrogio C; Köhler J
EBioMedicine; 2019 Nov; 49():106-117. PubMed ID: 31668570
[TBL] [Abstract][Full Text] [Related]
10. Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase.
Ruess DA; Heynen GJ; Ciecielski KJ; Ai J; Berninger A; Kabacaoglu D; Görgülü K; Dantes Z; Wörmann SM; Diakopoulos KN; Karpathaki AF; Kowalska M; Kaya-Aksoy E; Song L; van der Laan EAZ; López-Alberca MP; Nazaré M; Reichert M; Saur D; Erkan MM; Hopt UT; Sainz B; Birchmeier W; Schmid RM; Lesina M; Algül H
Nat Med; 2018 Jul; 24(7):954-960. PubMed ID: 29808009
[TBL] [Abstract][Full Text] [Related]
11. Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer.
Kim JY; Welsh EA; Fang B; Bai Y; Kinose F; Eschrich SA; Koomen JM; Haura EB
Mol Cancer Res; 2016 Oct; 14(10):1019-1029. PubMed ID: 27422710
[TBL] [Abstract][Full Text] [Related]
12. Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models.
Ji H; Wang Z; Perera SA; Li D; Liang MC; Zaghlul S; McNamara K; Chen L; Albert M; Sun Y; Al-Hashem R; Chirieac LR; Padera R; Bronson RT; Thomas RK; Garraway LA; Jänne PA; Johnson BE; Chin L; Wong KK
Cancer Res; 2007 May; 67(10):4933-9. PubMed ID: 17510423
[TBL] [Abstract][Full Text] [Related]
13. PIK3CA(H1047R) Accelerates and Enhances KRAS(G12D)-Driven Lung Tumorigenesis.
Green S; Trejo CL; McMahon M
Cancer Res; 2015 Dec; 75(24):5378-91. PubMed ID: 26567140
[TBL] [Abstract][Full Text] [Related]
14. Requirement for Ras/Raf/ERK pathway in naringin-induced G1-cell-cycle arrest via p21WAF1 expression.
Kim DI; Lee SJ; Lee SB; Park K; Kim WJ; Moon SK
Carcinogenesis; 2008 Sep; 29(9):1701-9. PubMed ID: 18296682
[TBL] [Abstract][Full Text] [Related]
15. Blockade of the IL-6 trans-signalling/STAT3 axis suppresses cachexia in Kras-induced lung adenocarcinoma.
Miller A; McLeod L; Alhayyani S; Szczepny A; Watkins DN; Chen W; Enriori P; Ferlin W; Ruwanpura S; Jenkins BJ
Oncogene; 2017 May; 36(21):3059-3066. PubMed ID: 27893707
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-6 production induced by leptin treatment promotes cell proliferation in an Apc (Min/+) colon epithelial cell line.
Fenton JI; Hursting SD; Perkins SN; Hord NG
Carcinogenesis; 2006 Jul; 27(7):1507-15. PubMed ID: 16597643
[TBL] [Abstract][Full Text] [Related]
17. Induction of interleukin-8 secretion and activation of ERK1/2, p38 MAPK signaling pathways by thrombin in dermal fibroblasts.
Wang L; Luo J; Fu Y; He S
Int J Biochem Cell Biol; 2006; 38(9):1571-83. PubMed ID: 16697690
[TBL] [Abstract][Full Text] [Related]
18. MAP4K4 is a novel MAPK/ERK pathway regulator required for lung adenocarcinoma maintenance.
Gao X; Chen G; Gao C; Zhang DH; Kuan SF; Stabile LP; Liu G; Hu J
Mol Oncol; 2017 Jun; 11(6):628-639. PubMed ID: 28306189
[TBL] [Abstract][Full Text] [Related]
19. Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer.
Kitai H; Ebi H; Tomida S; Floros KV; Kotani H; Adachi Y; Oizumi S; Nishimura M; Faber AC; Yano S
Cancer Discov; 2016 Jul; 6(7):754-69. PubMed ID: 27154822
[TBL] [Abstract][Full Text] [Related]
20. Cytosolic DNA sensor AIM2 promotes KRAS-driven lung cancer independent of inflammasomes.
Alanazi M; Weng T; McLeod L; Gearing LJ; Smith JA; Kumar B; Saad MI; Jenkins BJ
Cancer Sci; 2024 Apr; ():. PubMed ID: 38594840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
